CHARLOTTE, N.C.; March 7, 2024 (Business Wire) – Catawba Research, a prominent global clinical research organization (CRO), today introduced Julie Arnold as its vice president of project management. The continued addition of top-tier talent to the leadership team exemplifies Catawba Research’s unwavering commitment to partnering in the advancement of groundbreaking new drugs, devices and diagnostics.
With a 20-year career, distinguished by leadership across multiple therapeutic areas, Julie is a pivotal addition to Catawba Research’s growing operational team. Previously the Senior Vice President of Project Management at Elligo Health Research® and holding key roles at Syneos Health, Julie’s experience strategically positions her to optimize Catawba Research’s clinical and project management teams and processes — ensuring a seamless continuation of quality-driven, on-time project delivery.
“I couldn’t be more excited about the addition of Julie to our leadership team. Her outstanding track record of project leadership and her strategic prowess align seamlessly with our vision for the future. By bringing in talented leaders like Julie, Catawba Research is poised for continued growth, consistently exceeding our customers’ expectations,” said Andy Silverman, Ph.D., CEO at Catawba Research.
In her role, Julie will be dedicated to ensuring operational efficiency and supporting the continued and successful project outcomes that have been at the core of Catawba Research’s industry reputation for the past decade. Her expertise and oversight are set to play a pivotal role in the company’s mission to bring groundbreaking therapies to underserved populations through continuous innovation and collaborative partnerships with sponsors, vendors and sites.
About Catawba Research
Catawba Research is a leading contract research organization specializing in clinical research and development services for the pharmaceutical, biotechnology, and medical device industries. With a strong commitment to quality, innovation, and client satisfaction, Catawba Research delivers comprehensive solutions to advance healthcare products from concept to market. For more information, please visit www.catawbaresearch.com.
CHARLOTTLE, N.C.; Feb. 29, 2024 (Business Wire) – Catawba Research, a prominent global clinical research organization (CRO), welcomes Syed Faridi as its Vice President of Global Business Development. This strategic expansion of Catawba Research’s leadership team underscores its commitment to remain well-positioned in the dynamic clinical trials market to exceed expectations, drive innovation, and deliver even greater value to its clients and stakeholders.
Syed, an industry veteran with nearly two decades of experience in clinical research, brings an unparalleled level of expertise as a sales leader. His track record of consistently surpassing targets and fostering deeply collaborative client relationships speaks volumes. Having made significant contributions at Clinical Ink, Medidata Solutions, and Parexel, Syed's arrival is a game-changer for Catawba Research, elevating its ability to drive business and accelerate revenue growth.
"I am thrilled about Syed joining our leadership team. His ability to be a true partner to his customers is key to our organization’s values, and his business development expertise is an asset in further establishing Catawba Research as a market leader. The consistent recruitment of top-tier leaders like Syed ensures that we not only maintain, but elevate our trajectory of unparalleled growth," said Andy Silverman, Chief Executive Officer (CEO) at Catawba Research.
In his role, Syed will spearhead the cultivation and expansion of strategic client relationships, champion transformative sales and marketing practices, and develop and execute go-to-market strategies that demonstrate how Catawba Research’s experience and expertise align with the industry’s needs. His arrival further highlights Catawba Research's dedication to strong and innovative industry collaborations to help patients in need.
About Catawba Research
Catawba Research is a leading contract research organization specializing in clinical research and development services for the pharmaceutical, biotechnology, and medical device industries. With a strong commitment to quality, innovation, and client satisfaction, Catawba Research delivers comprehensive solutions to advance healthcare products from concept to market. For more information, please visit www.catawbaresearch.com.
CHARLOTTE, N.C.; Feb. 6, 2024 – Catawba Research, a leading global clinical research organization (CRO) that has established itself as a trusted partner in the development of new drugs, devices, and diagnostics with a strong focus on delivering high-quality tech-enabled research solutions, announced a new collaboration with Bingli Inc., which provides AI- guided diagnosis, disease management, and navigation for patients and healthcare providers. All Catawba’s clinical studies may now offer candidates pre-screening via Bingli’s smart clinical trial technology that includes rigorous disease scoring system outcomes and delivers a highly enriched candidate pool for real-time recruitment management.
“At Catawba Research, we are creating value in clinical research by identifying and incorporating the best technology solutions to speed recruitment, the biggest challenge currently facing our industry,” said Catawba Chief Executive Officer Andrew Silverman, Ph.D. “Partnering with Bingli gives us a powerful tool to streamline participation, reduce site burden, and save time for potential participants as they explore their clinical trial options.”
Applying Bingli’s technology platform will allow Catawba to reduce trial costs, eliminating a higher proportion of ineligible subjects compared to traditional pre-screening methods. The AI solution sends approximately 3% of candidates to sites, reducing failed screens by up to 75%. With a Bingli referral, a candidate is three to four times as likely to be eligible. Bingli delivers extraordinary value to sponsors and CROs by reducing site burden and delivering candidates highly likely to convert to enrolled subjects.
“Bingli’s candidate pre-screening application was added to our overall healthcare AI, self-learning platform to quickly provide real-time, deep understanding of pre-screening eligibility results,” said Bingli U.S. Chief Medical Officer Cees Wortel, M.D., Ph.D. “Our solution uses a unique, smart white box AI technology that incorporates sophisticated disease ratings aided by examples, such as diagnostic example images and eligibility assessments. At Bingli we care about clinical trial participation as a cornerstone of healthcare and health provision and our solution delivers shorter timelines and lower site workload all while increasing the success potential of each participant asynchronously.”
About Catawba Research
Catawba Research is a leading contract research organization specializing in clinical research and development services for the pharmaceutical, biotechnology, and medical device industries. With a strong commitment to quality, innovation, and client satisfaction, Catawba Research delivers comprehensive solutions to advance healthcare products from concept to market. For more information, please visit www.catawbaresearch.com.
About Bingli Inc.
Bingli delivers person centered, digital health solutions through dynamic, intelligent medical history and patient assessments. Bingli’s AI-powered medical practice and clinical research optimization platform is built around self-learning diagnostic reasoning and virtual patient engagement solutions for both patients and healthcare professionals. For more information, please visit www.bingli.us.
CHARLOTTE, N.C.; Dec. 6, 2023 – Catawba Research, a leading global clinical research organization (CRO) that has established itself as a trusted partner in the development of new drugs and therapies, with a strong focus on delivering high-quality research solutions, announced a new partnership with Elligo Health Research, the largest healthcare-enabling research organization, that will expand access to clinical trials. All Catawba’s clinical studies will now be available through Elligo’s new Study Marketplace platform to drive participation and increase efficiencies for research sites and sponsors.
“At Catawba Research, we are focused on driving innovation in clinical research and delivering agile solutions across an evolving portfolio of therapeutic areas,” said Catawba CEO Andrew Silverman, Ph.D. “This fits our mission and partnering with Elligo helps create greater access to research as studies are being delivered to hundreds of experienced research and healthcare-first sites.”
Through Study Marketplace, Catawba’s studies are listed to more than 500 subscribing sites that can easily apply for those studies and track progress. Sites can quickly browse a curated portfolio of available studies that are the right fit for their site, apply for those of interest, track progress, and collaborate among team members. Ultimately, sites are receiving more effective site selection and patient recruitment, leading to accelerated timelines for trials.
“Study Marketplace was built to create more transparency and streamline the sales and site selection process between clinical trial sponsors, clinical research organizations (CROs), and sites,” said Elligo CEO John Potthoff, Ph.D. “At Elligo, we understand how challenging it is for sites to identify new study opportunities and manage the sales cycle. Moving Catawba trials from a manual process to Study Marketplace will allow sites to avoid jumping between countless systems and communication methods to manage trials, which means more time can be spent on trial execution and patient care.”
About Catawba Research
Catawba Research is a leading contract research organization specializing in clinical research and development services for the pharmaceutical, biotechnology and medical device industries. With a strong commitment to quality, innovation and client satisfaction, Catawba Research delivers comprehensive solutions to advance health care products from concept to market. For more information, please visit www.catawbaresearch.com.
CHARLOTTE, N.C.; Oct. 26, 2023 (Business Wire) — Catawba Research, a leading clinical research organization with a goal to become the world’s most trusted CRO, is announcing changes to its executive leadership team. Effective today, Catawba’s Founder, Zaidoon A. Al-Zubaidy, is transitioning his day-to-day leadership responsibilities to Dr. Andy Silverman. Al-Zubaidy will become executive chairman where he will support customer relationships and provide mentorship to the executive leadership team. Silverman will expand his responsibilities from operational leadership as chief operating officer (COO) to driving the entire organization to meet its growth targets as the chief executive officer (CEO).
Silverman was recruited to Catawba by Liberty Lane Partners because of his extensive background in clinical research built off a 30-year career with PPD, INC Research and Syneos Health. “Since joining the firm in early 2022, Andy has exceeded our expectations at every step. He has been instrumental in establishing market leading operational capabilities at Catawba that have positioned the company for its next phase of growth. His leadership has made an impact on all stakeholders and given us confidence that he will succeed in his expanded role,” said Nick Goldstein, managing director of Liberty Lane Partners.
“I am honored to be appointed CEO of Catawba Research,” said Silverman. “Building on the remarkable foundation that Zaidoon and our dedicated team have established, we will continue our mission to drive innovation in clinical research and deliver agile solutions across an evolving portfolio of therapeutic areas to our clients and partners.”
As Executive Chairman, Al-Zubaidy will ensure Catawba maintains its dedication to its core values as it grows. “I am extremely proud of Catawba Research’s accomplishments since our founding in 2014. And I look forward to serving as a mentor and partner to our seasoned executive team as we pursue our next leg of growth,” said Al-Zubaidy. “While I’ll be stepping away from day-to-day operations, I will make sure Catawba remains an agile, responsive and trusted partner to our sponsors. I am extremely confident with Andy’s leadership and vision, we will continue our outstanding history of delivering excellence in clinical research services.”
Please join us on this journey and wish Andy the best of luck in his new role.
About Catawba Research
Catawba Research is a leading contract research organization specializing in clinical research and development services for the pharmaceutical, biotechnology, and medical device industries. With a strong commitment to quality, innovation, and client satisfaction, Catawba Research delivers comprehensive solutions to advance healthcare products from concept to market. For more information, please visit www.catawbaresearch.com.
CHARLOTTE, N.C.; March 30, 2023 – Catawba Research, a full-service contract research organization (CRO) for innovative trial management, is delighted to announce Andy Silverman, Ph.D., has joined its leadership team as its chief operating officer (COO).
Dr. Silverman joins a leadership team with more than 100 years of clinical research experience and an expansive and evolving portfolio of therapeutic success. Andy will be an active part of a dedicated management team that provides executive-level insights that guarantee protocol compliance and keep every component of a project on track. Dr. Silverman has 30+ years of deep clinical trial and executive experience within the CRO space, most recently as executive vice president, global operations at Syneos Health. Prior to his global role, Andy held several executive roles across the CNS division at INC Research (now Syneos) for over 15 years. Dr. Silverman was the co-founder and COO of startup CRO, Tanistry, and associate director at both PPD and Pharmaco.
“Dr. Silverman brings an immense level of specialized expertise that will help unlock new possibilities in trial management and health care,” said Catawba President & CEO Zaidoon A. Al-Zubaidy. “As our therapeutic portfolio is still growing, he’ll bring insights that leverage our track record of success in dermatology and women’s health into more recent triumphs in pulmonary, autoimmune and neurology research, all while continuing to ensure our clinical trials finish on time, on budget and with exemplary quality. Catawba Research is a place that cares about people — we cannot do what we do without positive leadership and a team of experts that take on challenges of clinical trials.”
About Catawba Research
Catawba Research is a full-service contract research organization (CRO) with a passion for providing innovative trial management to pharmaceutical, device, formulation development and biotechnology companies. Founded in 2014, Catawba has over 100 years of combined C-suite leadership experience and an expansive and evolving portfolio of therapeutic success. More agile and cost-conscious than your average CRO, Catawba utilizes consistent scientific engagement and fiscally responsible planning to stay on time and on budget. In fact, while only 20% of clinical trials finish on time, 70% of all clinical trials partnered with Catawba Research either meet or exceed timeline objectives.
Catawba Research launched seven years ago. As we set out to build a world-class, full-service contract research organization, our journey quickly led us to many wonderful milestones. These accomplishments include dozens of agency approvals, a site network, and a rapidly-expanding presence around the globe.
Now, we’re proud to unveil the next level of the Catawba Research push. Recently, our organization completed the move of its U.S. headquarters to a larger, more modern space. While still located in the same corporate building, Catawba Research’s new suite number is 120.
The change of home office scenery comes as the result of our fast growth! We’re so grateful to share this news with those that drive the Catawba Research mission: Our dedicated team, sponsors, and friends.
St. Cloud Capital is pleased to announce an investment in Charlotte, North Carolina-based Catawba Research. St. Cloud has partnered with a financial investment firm focused on control investments in the life sciences and industrial sectors to support Catawba's next phase of growth. It is an investment out of St. Cloud's third fund, which has committed capital of $250 million.
Catawba is a vertically integrated contract research organization ("CRO") providing clinical management services to pharmaceutical and biotechnology companies globally. The Company focuses on Phase II – IV trials across the dermatology, women's health, ophthalmology and gastroenterology therapeutic areas. Catawba manages clinical end point trials for New Drug Applications ("NDA") and Abbreviated New Drug Applications ("ANDA"). The Company has established a global footprint with site relationships across the U.S., Central America and India. Since 2014, Catawba Research has engaged in nearly 50 clinical trials in 13 indications, achieving 15 agency approvals in the U.S. and Canada. The Company is headquartered in Charlotte, NC with additional locations in Texas, New Mexico and Michigan. The Company also provides data management, biostatistics, medical writing and clinical CRO services through its location in Mumbai, India.
Zaidoon A. Al-Zubaidy, Chief Executive Officer of Catawba is excited to ally with St. Cloud to continue the Company's trajectory. "Catawba Research is excited to be a part of the St. Cloud story and we look forward to a successful journey with our new partners. With the support from St. Cloud, Catawba Research is confident of becoming one of the premier global clinical research providers. This is an exciting time for our team and our valued and loyal sponsors."
St. Cloud Capital Managing Partner Kacy Rozelle commented, "We are extremely pleased with the opportunity at Catawba and look forward to collaborating with management and our financial partners in the Company's next phase of growth."
About St. Cloud Capital
St. Cloud Capital is a Los Angeles, CA-based private investment firm that provides growth capital to the lower middle market (companies with annual revenues generally between $10 million and $150 million) throughout the United States. St. Cloud typically invests $5 million – $20 million in companies across a wide range of industries in every layer of the capital structure, including senior secured debt, subordinated debt, and preferred and common equity. St. Cloud's investment discipline includes non-control and control investments, and involves partnering with strong management teams or experienced industry entrepreneurs.
